[Determine and parallel analysis of three kinds of PAEs in serum for obese children]

Ping Li1, Xingbi Dai, Hong Dan

  • 1School of Public Health, Chongqing University of Medical Sciences, Chongqing 400016, China.

Insights

Obese children aged 10-12 show higher serum levels of certain phthalate esters (PAEs), specifically dibutyl phthalate (DBP) and diethylhexyl phthalate (DEHP). This suggests PAEs may contribute to health issues in obese youth.

Area of Science:

  • Environmental health
  • Pediatric endocrinology
  • Analytical chemistry

Context:

  • Phthalate esters (PAEs) are common endocrine-disrupting chemicals.
  • Childhood obesity is a growing global health concern.
  • Exposure to PAEs is widespread, with potential health implications.

Purpose:

  • To quantify and compare serum concentrations of specific PAEs (DEP, DBP, DEHP) in obese versus normal-weight children aged 10-12 years.
  • To assess the association between obesity and elevated PAE levels in this pediatric cohort.
  • To evaluate the potential harm of PAEs in obese children.

Summary:

  • Serum samples from 36 obese and 36 normal-weight children were analyzed for DEP, DBP, and DEHP using RP-HPLC.
  • Significantly higher median serum levels of DBP and DEHP were found in obese children compared to normal-weight children (P < 0.01).
  • Obese children exhibited higher proportions of individuals with elevated PAE levels.

Impact:

  • Findings indicate a significant correlation between childhood obesity and increased exposure to DBP and DEHP.
  • This study highlights the potential health risks associated with PAE exposure in the context of pediatric obesity.
  • Results underscore the need for further research into PAE toxicity and preventative strategies in vulnerable pediatric populations.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...